🟢 Nasus Pharma is trading 8.4% up today after FDA clearance for its NS002 IND application

Nasus Pharma is trading 8.4% higher at $3.69 after the U.S. FDA cleared its Investigational New Drug (IND) application for NS002, an intranasal epinephrine powder designed to treat anaphylaxis.

• The FDA decision represents a major development milestone and provides a clear company-specific catalyst for the stock's advance, even as broader U.S. markets trade lower.
• The company plans to initiate a pivotal study for the candidate in the fourth quarter of 2026, with topline results currently expected in the first quarter of 2027.